Jazz Pharmaceuticals Plc (JAZZ) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Jazz Pharmaceuticals Plc  (NASDAQ: JAZZ)


Jazz Pharmaceuticals Plc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Jazz Pharmaceuticals Plc's ROA in the second quarter of 2026?
Jazz Pharmaceuticals Plc achieved a return on average assets (ROA) of 8.19 % in its second quarter of 2026, this is above JAZZ's average return on assets of 7.41%.
Jazz Pharmaceuticals Plcs assets during the 12 months ending in the second quarter of 2026 are valued at $11 billion

Despite the company's net income deteriorating, Jazz Pharmaceuticals Plc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 113 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2496, from total ROA ranking in the first quarter of 2026 at 3306.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 1.25 % 2.82 % 1.99 % -2.72 % 1.93 %
Y / Y Net Income Change - - 6.45 % 16.91 % -
Net Income (TTM) in million 941 29 -356 -368 -405
Return On Assets (TTM) 8.19 % 0.26 % -3.13 % -3.26 % -3.55 %
JAZZ's Total Ranking # 2496 # 3306 # 2910 # 2923 # 1351
Total Assets (TTM) in million 11,081 11,860 11,659 11,356 10,944
Seq. Total Assets Change -6.57 % 1.72 % 2.67 % 3.77 % -5.12 %
Seq. Net Income Change -34.22 % 44.06 % -19.08 % - -

JAZZ's 5 Years Annual ROA >> Back to JAZZ Management Effectiveness >> Compare JAZZ ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 44
Sector # 114
Overall # 745

Return On Assets Statistics
High Average Low
63.24 %
7.41 %
-3.62 %
(Dec 31 2011)   (Mar 31 2022)





Financial Statements
Jazz Pharmaceuticals Plc's Assets $ 11,081 million JAZZ's Balance sheet
Jazz Pharmaceuticals Plc's Income $ 193 million Quarterly JAZZ's Income Statement
JAZZ's Income by Division See JAZZ's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -7.2 % 4.72 % 4.36 % -12.74 % 95.69 %
Total Assets in million 10,609 11,432 10,917 10,460 11,988
Y / Y Net Income Change - 35.02 % - - -
Net Income in million -356 560 415 -224 -330
Annual Return On Assets -3.36 % 4.9 % 3.8 % -2.14 % -2.75 %

JAZZ's 5 Years Annual ROA >> Back to JAZZ Management Effectiveness >> Compare JAZZ ROA to its Competitors



More Return On Assets Ratios
JAZZ's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
JAZZ's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for JAZZ's Competitors
Subscribers only: Roa for Jazz Pharmaceuticals Plc's Suppliers
Subscribers only: Return On Assets for JAZZ's Customers

You may also want to know
JAZZ's Roi JAZZ's Inventory Turnover Ratio JAZZ's Growth Rates JAZZ's Dividend Comparisons
JAZZ's Profitability Ratios JAZZ's Asset Turnover Ratio JAZZ's Dividend Growth
JAZZ's Roe JAZZ's Valuation Ratios JAZZ's Financial Strength Ratios JAZZ's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %
Arcutis Biotherapeutics Inc   14.23 %
Harmony Biosciences Holdings inc   14.15 %
Biolife Solutions Inc   14.09 %
Aveanna Healthcare Holdings Inc   13.82 %
West Pharmaceutical Services Inc   13.64 %
Medinotec Inc   13.38 %
Puma Biotechnology Inc   13.28 %

Date modified: 2026-09-12T18:36:12+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.